Clinic Sales & Onboarding Lead | https://strello.health
Strello is an AI front desk for Canadian medical clinics. It answers calls, books and moves appointments, and works directly inside the clinic's EMR. We're physician-founded (I'm a practising rheumatologist), and the product came out of our own front-desk turnover problems.
What you'll do: - Own inbound leads and respond fast. Screen for fit first: are they on an EMR we integrate with, and is Strello the right answer for their phones?
- Run discovery and demo calls with physicians and clinic managers, then quote, close, send contracts and payment links, and keep the CRM current.
- Lead onboarding: workflow meetings with clinic staff, phone and EMR access, and launch coordination with our engineers.
- Stay the go-to contact after launch, and bring what you hear back to the product team.
You might be a fit if you've worked in sales, or clinic operations (MOA, coordinator, manager), or healthcare SaaS account management, or customer success.
You should be comfortable on the phone and on video with physicians, organized enough to run many clinics in parallel, and happy to help write the playbook at an early-stage company.
Apply: [email protected] with a few lines on the clinics or customers you've worked with.
But to be clear: this is an in person (Toronto) / remote hybrid position.
If your CV doesn’t have a locale, please confirm your willingness to come in person/relocate
Strello Health builds AI voice agents for healthcare. We’re post-seed, generating revenue, and scaling quickly.
You’ll work directly with the founders to build the core infrastructure behind real-time voice conversations, including audio streaming, LLM orchestration, APIs, integrations, observability, and production systems.
We’re looking for engineers with experience in backend or platform development, distributed systems, APIs, Linux, and building reliable systems from 0→1. Co-op experience counts, and we’re hiring across experience levels.
Bonus: WebRTC/WebSockets, ML or LLM infrastructure, Node.js/TypeScript, Python, Docker, Kubernetes, or open-source contributions.
Tech stack: TypeScript/Node.js and Python.
Email: [email protected]
Although this research area is the most promising avenue for long COVID -- wrt biologic rationale -- the major anti-viral trials for long COVID were negative.
STOP-PASC trial [2] and PAXLC [3] were both 15-day courses of Paxlovid and showed no benefit across patient reported outcomes.
The real question however, is whether anti-virals have benefit in patients with active viral replication. Like only cases of long COVID can be implicated to viral persistence.
STOP-PASC did collect stool PCR at baseline, but every tested sample was negative. PAX LC later reported a exploratory biomarker analysis of 82 PAX LC participants did measure circulating SARS-CoV-2 S1 and full-length Spike, and wasn't powered to find a difference. Notably, spike presence doesn't necessarily mean active viral replication [4].
As an aside, mchusma's post is probably right. Viral disease is not being associated with more and more long term diseases. EBV is being linked to MS, cervical cancer to HPV, and so on.
[1] https://www.sciencedirect.com/science/article/pii/S147330992... [2] https://jamanetwork.com/journals/jamainternalmedicine/fullar... [3] https://pubmed.ncbi.nlm.nih.gov/40188838 [4] www.medrxiv.org/content/10.64898/2026.02.24.26347001v1.full
At the top of the evidence hierarchy is N-of-1 trials (and below that are high quality meta-analyses of trials). Nothing is more informative about treatment response in a person than testing it in that person. This is the heart of personalized medicine, and exactly for the reason you stated: Different interventions work differently for different people.
And any practitioner worth their salt is unsurprised by this headline. A great example is that illness and inflammation increase insulin resistance via counter-regulatory hormones.
You got one thing right, intuition often turns out to be wrong. That is why the vast majority experimental therapeutics built on great ideas never get passed initial testing.
Your model makes predictions. Prove they’re worth salt.
However you’re right to presume that small studies are likely to be lower quality, often because they’r observational as opposed to randomized studies.
You suggest something better: look for tissue level markers.
The immunotherapy revolution (ie CTLA/PD1 molecules), you’ll recognize that leveraging the immune system is brilliantly effective.
Presumably stealth genes do not evolve first, but rather proliferative genes. And this is why any chronic damage triggers cancer because renewal is a replicative process, and replications begets copy errors. wanderers and passersby will have to recognize I’m simplifying.
I have a great lateral. Not sure if you have the funds to try two things, but TCR characterization is a wonderful idea. At least thats the best way to do it, as I see it. has many application beyond cancer
Good luck!
Generally hydroxychloroquine is used in mild rheumatoid, whereas methotrexate is used in moderate-severe disease.
Inflammation in rheumatoid (and other inflammatory diseases) contribute to atherosclerosis and plaque buildup. Rheumatoid increases the risk of coronary disease by 1.5-2x.
That difference alone could account for the difference in dementia, particularly vascular dementia.
As an example, we showed that for-profit dialysis facilities in the US have about a 7% higher mortality rate. We did a meta-analysis and every study barring one found higher mortality in for-profit dialysis facilities. Other studies suggest one reason is lower referral rates for kidney transplantation. Higher mortality has also been shown in for profit hospitals.
Various cholesterol lowering drugs, statins being the most widely prescribed but certainly not the only class, show consistent relationship with cholesterol lowering and reduced risk of MACE (MI, stroke).
Plaque is made of foam cells that consume cholesterol. They grow and obstruct arteries, and eventually rupture causing critical flow obstructing events.
Perhaps diet, exercise, and evidenced based treatments would be a good place to start.
The GLP1s have proven to have excellent efficacy for weight loss (and cardiovascular mortality in diabetics). Their numbers approach bariatric surgery (>10% body weight in the obese).
People keep the weight off too. Here's one study showing 5kg on average weight loss at 5 years according to this study: https://www.mdpi.com/1660-4601/17/1/207/pdf
The new recommendation is that aspirin should not be used to prevent heart attack in those without a history of heart disease (ie avoid routine aspirin for "primary prevention"). Aspirin for primary prevention has always been a grey area. The reversal came after a large trial in the New England Journal of Medicine looking at this. The trial showed the decrease in cardiovascular events was balanced by a similar increase of bleeds. So it's still grey because some people would prefer to bleed because blood is easily replaceable, your heart is not.
What remains clear is that people who have had heart attacks, strokes, or peripheral arterial disease should in most cases continue their anti-platelet agent.
If I had to hazard a guess, it may be the market isn't attractive enough for competitors to establish a national supply chain. Or there's some sort of collusion at play.
To me this represents further evidence why public goods should be left out of the hands of private for profit organizations for whom disease is simply an externality to capitalize on.
Here's the tale: If you have obstruction of your bile ducts below the liver or gallbladder, usually gallstones or sometimes neoplasm, you need an endoscopic retrograde cholangiopancreatography (ERCP) for extraction or sampling.
ERCP is sticking a tube down the throat, stomach, small intestines into a tiny opening at the ampulla of Vater to access the bile ducts. Sometimes this process causes inflammation of the ampulla and associated ducts leading to blockage, and can lead to pancreatitis due to back flow and pressure, because the pancreas also excretes its digestive enzymes via the ampulla).
A few trials circa 2015 showed rectal indomethacin reduced the risk of post-ERCP pancreatitis, and eventually it made its way into the guidelines. It is the only proven preventative treatment, so they have a natural monopoly.
Hope that helps.
Undoubtedly, masks of any quality work. Airborne viruses still exist in secretions (likely, in much higher concentrations). Secretions sometimes even carry living cells, would you imagine (in fact the #1 cause of sputum sample contamination for C&S; the bane of internists everywhere). High velocity events certainly increase the environment-load of secretion and thereby virus.
You don't need evidence in all cases. Im sorry to say, to the otherwise curious-minded, this is one of those cases.
Their most impressive work is in PTSD. In Phase 2 trials, they took people with established PTSD (for years) and undertook ~3 guided psychotherapy sessions with MDMA. Within 2 months, 53% no longer met criteria for PTSD and at 12 months 68% didn't.
Far more efficacious that anything else we have. Powerful tool for psychologic healing.
1. The threat to jobs is in the air upon us, UBI or not. Watch its landing, the Gini is out of the bottle.2. Current models will make good enough general AI, not hard just tedious. They will not make genius AI that change paradigm due to optimizing for local maxima. ie Averaging responses to find truth doesn’t work when your answer set doesn’t know truth.3. This will be a revolution — you only...
Yes: the net impact on the environment is likely to be equivalent if imports and exports balance.
No: a major criticism of renewable energy is that it is less reliable. Achieving 100% is much more impressive without a handicap.
I'm still impressed though.
Though it's not quite 100% renewable energy unless the energy being imported is also renewable.
Basically, each node in a neural nets is unique akin to each neuron.